- Israel-based Clearmind Medicine ( NASDAQ: CMND ) is trading ~7% higher after pre-clinical results showed efficacy of its psychedelic-derived drug candidate MEAI for treating obesity and metabolic syndrome.
- The animals treated with MEAI showed increased energy, better fat utilization and weight loss of 20%, while reducing their overall fat mass and preserving their lean body mass.
- MEAI treatment showed normalization of insulin levels, improved glucose tolerance as well as reduced fat and triglycerides accumulation in the liver.
For further details see:
Clearmind rises 7% on efficacy of psychedelic-derived obesity treatment in pre-clinical trial